Bone-modifying agents for non-small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review

Jinyoung Kim; Chaiho Jeong; Jeongmin Lee; Jeonghoon Ha; Ki-Hyun Baek; Seohyun Kim; Tai Joon An; Chan Kwon Park; Hyoung Kyu Yoon; Jeong Uk Lim

doi:10.1053/j.seminoncol.2023.09.002

Bone-modifying agents for non-small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review

Semin Oncol. 2023 Jun-Oct;50(3-5):105-112. doi: 10.1053/j.seminoncol.2023.09.002. Epub 2023 Sep 14.

Authors

Jinyoung Kim¹, Chaiho Jeong², Jeongmin Lee³, Jeonghoon Ha⁴, Ki-Hyun Baek¹, Seohyun Kim⁵, Tai Joon An⁵, Chan Kwon Park⁵, Hyoung Kyu Yoon⁵, Jeong Uk Lim⁶

Affiliations

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
² Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
³ Division of Endocrinology and Metabolism, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
⁴ Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
⁵ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
⁶ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Electronic address: cracovian@catholic.ac.kr.

PMID: 37723018
DOI: 10.1053/j.seminoncol.2023.09.002

Abstract

During the course of lung cancer progression, bone metastases occur in about 40% of patients. Common complications associated with bone metastases in lung cancer patients include musculoskeletal pain, pathologic fractures, spinal cord compression, and hypercalcemia. We discuss the efficacy of bone-modifying agents (BMAs) in reducing skeletal-related events (SREs) and improving cancer-related outcomes, particularly in patients with stage IV non-small-cell lung cancer with bone metastases. In addition, the combined effects of BMAs with radiotherapy or immunotherapy in reducing SREs in patients with lung cancer and bone metastases are explored.

Keywords: Bone density conservation agents; Lung cancer; Metastases; Osteoporosis.

Publication types

Review